SBIR-STTR Award

Battery-powered implantable systems are now being used in a wide array of therapeutic and prosthetic applications such as cardiac pacemakers/defibrillators, drug pumps, and more recently, neurostimulators for Parkinson's, pain relief, and cochlear implants. For most of these applications, the energy-density and life of currently-available batteries is insufficient to enable fully-implantable systems, and the battery power supply must remain external. In Phase I of the proposed program, we intend to demonstrate that a new battery technology, thin-film rechargeable lithium, will enable fully-implantable systems, by demonstrating the feasibility for one particular application: a cochlear implant. This will require that we demonstrate the feasibility of achieving an energy-density of 500mWh/cc (3X to 4X current implantable rechargeable batteries), a 20-year life (5X to 10X current batteries), a 5- or 10-minute recharge capability (not available in current batteries), and improved safety (by using all solid-state battery materials, thereby eliminating the toxic liquid electrolyte in current batteries). In Phase I, we will fabricate individual battery cells and conduct tests to demonstrate these performance capabilities. In Phase II, we will complete the battery by stacking cells within a hermetically- sealed case, and produce a sufficient quantity of batteries for extensive in-house testing and evaluation by a major cochlear-implant manufacturer. Proposed Commercial Applications: Our initial battery will be designed for cochlear implants, which have current annual sales of approximately $ 425 million and expected to grow by approximately 20% annually. Upon completion of the cochlear demonstration battery, we will pursue the other implantable neuromodulation applications, which have current annual sales of $1.6 billion and expected to grow to $10 billion in 10 to 15 years. In addition to neuromodulation applications, our battery technology will be suitable for rechargeable batteries for hearing aids, currently estimated to be a $5 billion dollar industry.

Thesaurus Terms:
Implantable medical power source, thin-film battery, lithium battery, cochlear implant, neurostimulator power source, neuromodulation implant battery, hearing aid battery. Implantable battery-powered systems are increasingly being used for treating a wide array of neuromodulation applications including cochlear implants, neurostimulation for treating Parkinson's disease, tremors, epilepsy, chronic depression, chronic pain, obesity, angina, obsessive-compulsive disorder, and implantable drug pumps which deliver small precisely controlled doses of drugs directly to targeted sites in the body. For many applications, the energy-density and life of currently-available batteries is inadequate to enable fully-implantable neuromodulation systems. NanoEnergy(r), Front Edge Technology's (FET) novel, rechargeable, thin-film, lithium battery is enabling technology for the successful introduction of fully implantable neuromodulation devices

Battery-powered implantable systems are now being used in a wide array of therapeutic and prosthetic applications such as cardiac pacemakers/defibrillators, drug pumps, and more recently, neurostimulators for Parkinsons, pain relief, middle-ear implant and cochlear implant. For most of these applications, the energy-density and life of currently-available batteries are insufficient to enable fully-implantable systems and the battery frequently remains external. In Phase II, Front Edge Technology (FET) proposes to continue the development, it commenced in Phase I, of an advanced rechargeable battery for fully implantable hearing prosthetics devices such as cochlear implants and middle-ear implants. Relative to the state- of-the-art rechargeable batteries, the proposed battery has three times the energy density, three times the battery life and half the recharge time. During Phase II, FET will produce high capacity batteries by stacking high energy density Phase I cells in a novel manner such that overall high energy density is maintained. Sufficient quantities of batteries will be produced to support extensive in-house testing and evaluation by both a major cochlear-implant manufacturer and an implantable battery manufacturer. Previously in Phase I, FET successfully demonstrated (i) ultra-high energy density single layer cells (800Wh/L) (ii) very long cycle life (> 4000 cycles) and (iii) relatively fast recharge (6 minutes). Proposed Commercial Applications: Our initial battery will be designed for cochlear implants, which have current annual sales of approximately $ 425 million and expected to grow by approximately 20% annually. Upon completion of the cochlear demonstration battery, we will pursue the other implantable neuromodulation applications, which have current annual sales of $1.6 billion and expected to grow to $10 billion in 10 to 15 years. In addition to neuromodulation applications, our battery technology will be suitable for rechargeable batteries for hearing aids, currently estimated to be a $5 billion dollar industry.

Thesaurus Terms:
Implantable medical power source, thin-film battery, lithium battery, cochlear implant, neurostimulator power source, neuromodulation implant battery, hearing aid battery.

Public Health Relevance:
Battery-powered implantable systems are now being used in a wide array of therapeutic and prosthetic applications such as drug pumps, and neurostimulators for Parkinson's, pain relief, middle-ear implant and cochlear implant. For most of these applications, the energy-density and life of currently- available batteries are insufficient to enable fully-implantable systems and the battery frequently remains external. Front Edge Technology's novel, rechargeable, thin-film battery will enable the successful introduction of fully implantable cochlear implants, middle-ear implants and other implantable neuromodulation devices.

Thesaurus Terms:
Achievement; Achievement Attainment; Aging; Anodes; Area; Artificial Cardiac Pacemaker; Arts; Auditory Prosthesis; Auricular Prosthesis; Calendar; Caliber; Cardiac Pacemaker; Cathodes; Cell Count; Cell Number; Cells; Charge; Cochlear Implants; Cochlear Prosthesis; Data; Defibrillators; Deposit; Deposition; Development; Devices; Diameter; Drugs; Electric Shock Cardiac Stimulators; Electrolytes; Evaluation; Flr; Failure (Biologic Function); Film; Government; Half-Life; Half-Lifes; Hearing Aids; Housing; Idiopathic Parkinson Disease; Implant; In Element; Indium; Industry; Lewy Body Parkinson Disease; Li+ Element; Life; Life Cycle; Life Cycle Stages; Lithium; Manufacturer; Manufacturer Name; Medical; Medication; Middle Ear Implant; Pacemaker, Artificial; Pain; Painful; Paralysis Agitans; Parkinson; Parkinson Disease; Parkinson's; Parkinson's Disease; Parkinsons Disease; Performance; Persons; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase; Power Sources; Power Supplies; Primary Parkinsonism; Process; Property; Property, Loinc Axis 2; Prosthesis; Prosthetic Device; Prosthetics; Pump; Relative; Relative (Related Person); Safety; Sales; Senescence; Stimulators, Electrical, Cardiac, Shock; System; System, Loinc Axis 4; Technology; Temperature; Therapeutic; Thesauri; Thick; Thickness; Ti Element; Time; Titanium; Work; Auricular Prosthetic; Commercial Application; Design; Designing; Drug/Agent; Ear Prosthesis; Ear Prosthetic; Energy Density; Evaluation/Testing; Failure; Hearing Prosthesis; Hearing Prosthetic; Life Course; Meetings; Neural Control; Neural Regulation; Neuroregulation; New Technology; Novel; Public Health Relevance; Seal; Senescent